Business Standard

Wednesday, January 29, 2025 | 09:14 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Human trials of Chikungunya vaccine underway, announces Bharat Biotech

The inactivated virus vaccine was found to be safe and immunogenic in pre-clinical animal testing

Chikungunya, virus
Premium

Photo: Shutterstock

BS Reporter Hyderabad
Hyderabad-based vaccine manufacturer Bharat Biotech announced on Monday that phase-I of human clinical trials of Chikungunya vaccine was underway in India to evaluate the vaccine's safety, tolerability and immunogenicity.
The placebo-controlled study involving 60 healthy volunteers would test escalating doses of the vaccine in the prime-boost regimen, the company informed.
Bharat Biotech developed the CHIKV vaccine using an isolate of the virus from Indian epidemic. The inactivated virus vaccine developed by the in-house research and development team was found to be safe and immunogenic in pre-clinical animal testing, according to the company.
After successful completion of product development and pre-clinical testing, the candidate's

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in